Chain Bridge I, a blank check company also known as a special purpose acquisition company (SPAC), has announced that its Class A ordinary shares and units will be suspended from trading on The Nasdaq Capital Market as of today.
Following this suspension, the company's securities will be eligible for trading on the OTCQB Market under the symbol “CBRRF” for Class A ordinary shares, and on the Pink Open Market for warrants and units under the symbols “CBRGF” and “CBGGF,” respectively.
This move comes after Nasdaq determined to suspend trading due to non-compliance with continued listing standards. The delisting process will be finalized by Nasdaq with the filing of a Form 25-NSE with the U.S. Securities and Exchange Commission (SEC), which will remove Chain Bridge I's securities from Nasdaq's listing and registration.
Despite the delisting, Chain Bridge I remains optimistic about its ability to complete a planned business combination with Phytanix Bio, referred to as the Phytanix Business Combination. The company intends to apply for the relisting of its securities on Nasdaq upon completion of this merger. However, if the merger fails to materialize, the delisting could significantly affect the company's prospects, potentially leading to liquidation.
On Sunday, November 14, 2024, Chain Bridge I held an Extraordinary General Meeting of Shareholders where an amendment proposal was approved to extend the deadline for completing a business combination by one year, from November 15, 2024, to November 15, 2025. If a business combination is not achieved by the new deadline, the company will be required to dissolve and liquidate.
The company also reported that in connection with the shareholder meeting, approximately 550,947 Class A shares were redeemed for cash, amounting to approximately $6.3 million from the trust account. Following these redemptions, 3,014,736 Class A Ordinary Shares remain outstanding.
This news is based on recent SEC filings and represents a significant development for Chain Bridge I and its investors.
InvestingPro Insights
As Chain Bridge I (CBRGU) navigates its delisting from Nasdaq and potential merger with Phytanix Bio, InvestingPro data provides additional context for investors. The company's market capitalization stands at $114 million, reflecting its current valuation in the market.
Two key InvestingPro Tips are particularly relevant in light of recent developments. Firstly, CBRGU is "trading at a high earnings multiple," with a P/E ratio of 74.02. This high valuation could be influenced by investor expectations surrounding the potential Phytanix Business Combination. Secondly, the company's "short-term obligations exceed liquid assets," which may be a concern given the recent redemptions and the possibility of further liquidation if the merger doesn't materialize.
It's worth noting that CBRGU has been "profitable over the last twelve months," with a basic EPS of $0.15. However, the adjusted P/E ratio of 579.27 suggests that this profitability might not fully justify the current stock price.
For investors seeking a more comprehensive analysis, InvestingPro offers 4 additional tips that could provide valuable insights into Chain Bridge I's financial position and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.